These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35355244)

  • 21. Clinical research and methodology: What usage and what hierarchical order for secondary endpoints?
    Laporte S; Diviné M; Girault D;
    Therapie; 2016 Feb; 71(1):27-41. PubMed ID: 27080628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The fallback procedure for evaluating a single family of hypotheses.
    Wiens BL; Dmitrienko A
    J Biopharm Stat; 2005; 15(6):929-42. PubMed ID: 16279352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
    Hamasaki T; Evans SR; Asakura K
    J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
    Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
    Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
    Stallard N
    Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple comparisons with two controls for ordered categorical responses.
    Yang P; Hung Cheung S; Poon WY
    J Biopharm Stat; 2017; 27(1):111-123. PubMed ID: 26881877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-arm trials with multiple primary endpoints and missing values.
    Hasler M; Hothorn LA
    Stat Med; 2018 Feb; 37(5):710-721. PubMed ID: 29108137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A group sequential Holm procedure with multiple primary endpoints.
    Ye Y; Li A; Liu L; Yao B
    Stat Med; 2013 Mar; 32(7):1112-24. PubMed ID: 23239078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Method of balanced adjustment in testing co-primary endpoints.
    Kordzakhia G; Siddiqui O; Huque MF
    Stat Med; 2010 Aug; 29(19):2055-66. PubMed ID: 20683896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An enhanced mixture method for constructing gatekeeping procedures in clinical trials.
    Kordzakhia G; Brechenmacher T; Ishida E; Dmitrienko A; Zheng WW; Li DF
    J Biopharm Stat; 2018; 28(1):113-128. PubMed ID: 29239689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A note on tree gatekeeping procedures in clinical trials.
    Dmitrienko A; Tamhane AC; Liu L; Wiens BL
    Stat Med; 2008 Jul; 27(17):3446-51. PubMed ID: 18484599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mixture gatekeeping procedure based on the Hommel test for clinical trial applications.
    Brechenmacher T; Xu J; Dmitrienko A; Tamhane AC
    J Biopharm Stat; 2011 Jul; 21(4):748-67. PubMed ID: 21516567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extension of adaptive alpha allocation methods for strong control of the family-wise error rate.
    Li H; Sankoh AJ; D'Agostino RB
    Stat Med; 2013 Jan; 32(2):181-95. PubMed ID: 22806685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Step-up testing procedure for multiple comparisons with a control for a latent variable model with ordered categorical responses.
    Lin Y; Kwong KS; Cheung SH; Poon WY
    Stat Med; 2014 Sep; 33(21):3629-38. PubMed ID: 24757077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims.
    Jaki T; Parry A
    Pharm Stat; 2016 Jul; 15(4):362-7. PubMed ID: 27094960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.
    Lafaye de Micheaux P; Liquet B; Marque S; Riou J
    J Biopharm Stat; 2014; 24(2):378-97. PubMed ID: 24605975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.